GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Post-LOEguaifenesin and dextromethorphan hbr
ANDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE (guaifenesin and dextromethorphan hbr) by Dr. Reddy's Laboratories. Approved for expectorant [epc]. First approved in 2023.
Drug data last refreshed 18h ago
Mechanism of Action
Pharmacologic Class:
Expectorant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.